The unique solution for multimodality oncology follow-up Myrian® XL-Onco is the culmination of eight years of development of the Myrian platform.
Dedicated to oncology follow-up, it manages the sequencing of tasks essential for the management of the cancer patients with elevated efficiency and in strict complaince with the international RECIST rules, consensually established by European, Canadian and American authorities. The Cheson protocol whose parameters can be set by the user are also available.
Myrian XL-Onco was developed and validated jointly with leading French experts and makes Intrasense a world leader in oncology follow-up software applied to medical imaging.
It is intended for routine clinical practices of hospital treating cancer patients as well as pharmaceutical companies and CROs in the framework of phase I,II and III clinical trials to evaluate anti-cancer therapies.
Original Technologies
Automated retrieval of prior exams, dedicated clinical workflow obeying RECIST rules, automatic 3D registrations of examinations in elastic mode, automated production of reports and graphs
Applications
It is used to follow the course of a patient’s cancer by comparing the latest examination to prior results. This follow-up involves key steps managed by the software that considerably simplifies the radiologist’s work
First rate partners
The best specialised cancer teams contributed to the development of this module:
- Curie Institute (Paris, France)
- Pitié-Salpêtrière (AP-HP – Paris Public Hospitals Authority)(Paris, France)
- Hôpital Européen Georges Pompidou (AP-HP – Paris Public Hospitals Authority)(Paris, France)
- Civil Hospices of Lyon (HCL)(Lyons, France)
- Montpellier University Hospital (Montpellier France)
For more details, contact
JIGISH B MODI
Tel: 2506 5664
Mob: 98670 01110
Email: [email protected]
Skype: modi.medicare
- Advertisement -
Comments are closed.